Compare Orion Office REIT Inc (ONL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Orion Office REIT Inc vs Viatris Inc — how do they compare? Orion Office REIT Inc trades at $2.62 (market cap $151.74M), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Viatris Inc is far larger — about 135.1× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays the higher dividend (3%). Which is the better fit depends on your goals.
| ONL | VTRS | |
|---|---|---|
Market Cap | $151.74M | $20.50B |
Sector | Real Estate | Health |
52-Week High | $3.04 | $17.59 |
52-Week Low | $1.93 | $8.74 |
Enterprise Value | $635.39M | $32.71B |
Dividend Yield | 3% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONL trades at $2.67, up 1.52% with mixed technical signals showing bullish oscillators but bearish moving averages. The company faces significant fundamental challenges with revenue declining from $208M in 2022 to $147.65M in 2025 and deep net losses widening to -$139.31M. However, strategic reviews with Wells Fargo and JPMorgan and recent refinancing extensions provide some stability amid ongoing portfolio repositioning toward dedicated use assets.
The outlook remains challenging with persistent losses and declining revenue, though the strategic review and deleveraging progress offer potential catalysts. Key risks include execution of asset sales, office market headwinds, and negative cash flow from operations. Analyst sentiment is divided with 50% buy and 50% hold ratings, reflecting uncertainty about the turnaround strategy's success.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
